CIC
SLXP

Chase Investment Counsel’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Chase Investment Counsel’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-13,232
Closed -$2.07M – 111
2014
Q3 		$2.07M Sell
13,232
-3,328
-20% -$482K 0.74% 47
2014
Q2 		$2.04M Buy
16,560
+1,570
+10% +$174K 0.69% 49
2014
Q1 		$1.55M Sell
14,990
-100
-0.7% -$10.2K 0.53% 73
2013
Q4 		$1.36M Buy
+15,090
New +$1.2M 0.4% 79

Other funds holding SLXP

PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Chase Investment Counsel's SLXP Position: Q4 2014 in Review

Chase Investment Counsel sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q4 2014, closing a stake of 13,232 shares — an estimated $2.07M sold.

Chase Investment Counsel first reported a position in SLXP in Q4 2013 and held it in 4 quarters. The position peaked at $2.07M in Q3 2014. 347 funds tracked by Wall St. Rank hold SLXP as of Q4 2014.

  • Chase Investment Counsel reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q4 2014 after selling out during the quarter.
  • Chase Investment Counsel sold 13,232 SALIX PHARMACEUTICALS LTD DEL shares in Q4 2014, an estimated $2.07M.
  • Chase Investment Counsel first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q4 2013 and held it in 4 quarters.
  • Chase Investment Counsel's SALIX PHARMACEUTICALS LTD DEL position peaked at $2.07M in Q3 2014.
  • 347 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q4 2014.

Based on Chase Investment Counsel's 13F filing for Q4 2014, filed 3 Feb 2015.